Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALA NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00$0.00▼$0.00N/A-1.36745 shs432 shsMNKDMannKind$4.09-0.1%$3.72$2.23▼$6.51$1.27B1.095.60 million shs1.49 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-66.67%-66.67%0.00%0.00%MNKDMannKind+5.41%-3.76%+2.25%+48.73%+6.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00$0.00▼$0.00N/A-1.36745 shs432 shsMNKDMannKind$4.09-0.1%$3.72$2.23▼$6.51$1.27B1.095.60 million shs1.49 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-66.67%-66.67%0.00%0.00%MNKDMannKind+5.41%-3.76%+2.25%+48.73%+6.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/AMNKDMannKind 2.50Moderate Buy$8.97119.55% UpsideCurrent Analyst Ratings BreakdownLatest MNKD and CALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026MNKDMannKind Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)7/7/2026MNKDMannKind Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/1/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$11.005/7/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.005/7/2026MNKDMannKind HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.005/7/2026MNKDMannKind Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$3.50 ➝ $4.755/7/2026MNKDMannKind MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.004/28/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $8.00(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AMNKDMannKind$348.97M3.62$0.07 per share62.70($0.17) per share-24.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/AN/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)MNKDMannKind$5.86M-$0.07N/A34.04N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)Latest MNKD and CALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026MNKDMannKind-$0.02N/AN/AN/A$109.18 millionN/A5/6/2026Q1 2026MNKDMannKind-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/AMNKDMannKindN/A1.871.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/AMNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%MNKDMannKind2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences603.86 million4.55 millionNot OptionableMNKDMannKind400308.95 million300.92 millionOptionableMNKD and CALA HeadlinesRecent News About These Companies180 Wealth Advisors LLC Grows Holdings in MannKind Corporation $MNKDJuly 12, 2026 | marketbeat.comMannKind Corporation (MNKD) Up 20% Since Afrezza FDA ApprovalJuly 10, 2026 | finance.yahoo.comMannKind (NASDAQ:MNKD) Stock Rating Lowered by Zacks ResearchJuly 9, 2026 | marketbeat.comMannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Hold" RatingJuly 5, 2026 | americanbankingnews.comMannKind (NASDAQ:MNKD) Raised to Hold at Wall Street ZenJuly 5, 2026 | marketbeat.comMannKind (MNKD) Receives a Grant from Breakthrough T1DJuly 3, 2026 | insidermonkey.comIs MannKind Corporation (MNKD) A Good Stock To Buy Now?June 29, 2026 | finance.yahoo.comMannKind (NASDAQ:MNKD) Cut to Sell at Wall Street ZenJune 27, 2026 | marketbeat.comMannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1DJune 23, 2026 | globenewswire.comEcoR1 Capital LLC Acquires Shares of 1,660,000 MannKind Corporation $MNKDJune 18, 2026 | marketbeat.comApis Capital Advisors LLC Invests $6.81 Million in MannKind Corporation $MNKDJune 18, 2026 | marketbeat.comWells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”June 13, 2026 | insidermonkey.comWells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”June 13, 2026 | finance.yahoo.comADA26: T1 and T2 diabetes readouts from Roche, MannKind and LillyJune 9, 2026 | yahoo.comJim Cramer Says He Blessed MannKind as a Speculation OnlyJune 9, 2026 | finance.yahoo.comData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with ...June 6, 2026 | markets.businessinsider.comMannKind Corporation Presents New Clinical Data Supporting Afrezza and FUROSCIX at ADA 2026 Scientific SessionsJune 5, 2026 | quiverquant.comQData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) SystemsJune 5, 2026 | globenewswire.comMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib ...June 3, 2026 | finance.yahoo.comMannKind Corporation Advances Nintedanib DPI Program for IPF with Phase 1b INFLO-1 Study Data Expected in Q3 2026June 3, 2026 | quiverquant.comQMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFJune 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNKD and CALA Company DescriptionsCalithera Biosciences NASDAQ:CALA$0.0001 0.00 (0.00%) As of 07/15/2026 02:40 PM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.MannKind NASDAQ:MNKD$4.08 -0.01 (-0.12%) As of 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Why Conagra’s Dividend Cut Could Be the Best Thing for Investors Which Storage Stock Is Best Positioned to Win the AI Memory War? Cintas Keeps Beating Expectations—And the Story Isn’t Over Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
